Ulcerative colitis. Ulcerative colitis
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group consume 1000 mg metformin tablet (produced by Tehran Shimi Company) for two months after breakfast and evening meals. Intervention 2: Control
Sponsors
Sabzevar University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Patients have ulcerative colitis involving at least the rectosigmoid region with the activity confirmed by colonoscopy at the beginning of the study Patients with ulcerative colitis over 18 years of age Patients with mild to moderate recurrent ulcerative colitis with a disease activity index of 3 to 8 points with symptoms (recurrent episodes) for less than 4 weeks before the study
Exclusion criteria
Exclusion criteria: Patients with Crohn’s disease, diabetic mellitus, heart failure, and severe renal or hepatic failure. Pregnant or lactating women Patients with mild to moderate recurrent ulcerative colitis with a disease activity index of less than 3 and more than 8 points with symptoms (recurrent episodes) for less than 4 weeks before the study Patients with a past history of allergy to metformin Patients treated with systemic corticosteroids, anti-tumor necrosis factor (TNF) or cyclosporine in the last 8 weeks and during the study period Patients with any changes in the oral dose of 5-ASA or 6-mercaptopurine and azathioprine in the last 12 weeks and during the study. In addition, patients taking rectal 5-ASA or steroids 4 weeks before enrollment or during the 8-week study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determining disease activity index (DAI). Timepoint: Before the intervention and two months after the intervention. Method of measurement: Mayo Score/Disease Activity Index (DAI) for Ulcerative Colitis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mahdi Molavi
Sabzevar University of Medical Sciences
Outcome results
None listed